Italia markets close in 59 minutes

QURE Jun 2024 15.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,70000,0000 (0,00%)
In data: 02:33PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente4,7000
Aperto5,3100
Denaro4,6000
Lettera6,6000
Prezzo d'esercizio15,00
Scadenza2024-06-21
Min-Max giorno4,7000 - 5,4000
Contratto - Min-MaxN/D
Volume5
Open Interest12
  • GlobeNewswire

    uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

    ~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments in more than half of research and technology projects, centralizing operations, and streamlining organization ~ ~ Prioritizing continued development of AMT-130 in Huntington’s disease and near-term initiation of clinical trials for AMT-260 in refractory mesial temporal lobe epilepsy, AMT-162 in SOD1-

  • GlobeNewswire

    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The Company granted equity awards to 42 employees as a material inducement to commencing their employment. In the aggregate, those employees received 98,900 restricted share units and options to purchase 90,500 ordinary

  • GlobeNewswire

    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

    Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260